688177 Stock Overview
A biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, and other serious medical conditions in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bio-Thera Solutions, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.76 |
| 52 Week High | CN¥47.46 |
| 52 Week Low | CN¥18.00 |
| Beta | 0.47 |
| 11 Month Change | -13.34% |
| 3 Month Change | 8.69% |
| 1 Year Change | -47.41% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -18.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688177 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.8% | -1.9% | -2.8% |
| 1Y | -47.4% | -21.0% | 2.0% |
Return vs Industry: 688177 underperformed the CN Biotechs industry which returned -21% over the past year.
Return vs Market: 688177 underperformed the CN Market which returned 2% over the past year.
Price Volatility
| 688177 volatility | |
|---|---|
| 688177 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688177 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688177's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,171 | Shengfeng Li | www.bio-thera.com |
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, and other serious medical conditions in China and internationally. It offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, and metastatic cervical cancer; and BAT1806 for the treatment of rheumatoid arthritis, systemicjuvenile idiopathic arthritis, and cytokine release syndrome. The company also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn’s disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases.
Bio-Thera Solutions, Ltd. Fundamentals Summary
| 688177 fundamental statistics | |
|---|---|
| Market cap | CN¥9.01b |
| Earnings (TTM) | -CN¥377.67m |
| Revenue (TTM) | CN¥825.18m |
10.9x
P/S Ratio-23.9x
P/E RatioIs 688177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688177 income statement (TTM) | |
|---|---|
| Revenue | CN¥825.18m |
| Cost of Revenue | CN¥245.49m |
| Gross Profit | CN¥579.68m |
| Other Expenses | CN¥957.35m |
| Earnings | -CN¥377.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 70.25% |
| Net Profit Margin | -45.77% |
| Debt/Equity Ratio | 82.8% |
How did 688177 perform over the long term?
See historical performance and comparison